Hyaluronan-modified and regular multilamellar liposomes provide sub-cellular targeting to macrophages, without eliciting a pro-inflammatory response

Journal of Controlled Release

Volumn 160, Issue 2, 2012, Pages 388-393

  Glucksam Galnoy, Yifat ^a   Zor, Tsaffrir ^a   Margalit, Rimona ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Hyaluronan; Internalization; Liposomes; Macrophage; Targeting; TNF

Indexed keywords

ANTI-INFLAMMATORY ACTIVITY; ANTI-INFLAMMATORY DRUGS; BINDING AFFINITIES; BINDING CAPACITIES; BODY OF KNOWLEDGE; CELLULAR LOCALIZATION; CYTOKINE PRODUCTION; DRUG ACTION; DRUG-TARGETING; HYALURONAN; INTERNALIZATION; LY294002; MULTILAMELLAR; MULTILAMELLAR LIPOSOMES; MULTIPLE EQUILIBRIUM; SUB-CELLULAR; SURFACE-MODIFIED; TARGETING; UNILAMELLAR; WORTMANNIN;

BINDING ENERGY; CELL MEMBRANES; CELL PROLIFERATION; CYTOLOGY; DRUG PRODUCTS; LIPOSOMES; MOLECULAR BIOLOGY; SURFACE PROPERTIES; THERMODYNAMICS;

MACROPHAGES;

CYTOKINE; DRUG CARRIER; HYALURONIC ACID; LIPOPOLYSACCHARIDE; LIPOSOME; MULTILAMELLAR LIPOSOME; REGULAR UNILAMELLAR LIPOSOME; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BINDING AFFINITY; CELL PROLIFERATION; CELL SURFACE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG TARGETING; EQUILIBRIUM CONSTANT; INTERNALIZATION; LIPOSOMAL DELIVERY; NONHUMAN; PARTICLE SIZE; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; TARGET CELL; THERMODYNAMICS;

ANIMALS; ANTIGENS, CD44; BINDING SITES; CELL LINE; CYTOKINES; DRUG CARRIERS; FLOW CYTOMETRY; HYALURONIC ACID; INTRACELLULAR SPACE; LIPOSOMES; MACROPHAGE ACTIVATION; MACROPHAGES; MICE; MICROSCOPY, CONFOCAL; PARTICLE SIZE; SURFACE PROPERTIES;

EID: 84861710914     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2011.10.008     Document Type: Article

References (30)

1. A. Raz, C. Bucana, W.E. Fogler, G. Poste, and I.J. Fidler Biochemical, morphological, and ultrastructural studies on the uptake of liposomes by murine macrophages Cancer Res. 41 1981 487 494
2. J. Isaiah, I.J. Fidler, A. Raz, W.E. Fogler, L.C. Hoyer, and G. Poste The role of plasma membrane receptors and the kinetics of macrophage activation by lymphokines encapsulated in liposomes Cancer Res. 41 1981 495 504
3. A. Nardin, M.L. Lefebvre, K. Labroquère, O. Faure, and J.P. Abastado Liposomal muramyl tripeptide phosphatidylethanolamine: targeting and activating macrophages for adjuvant treatment of osteosarcoma Curr. Cancer Drug Targets 6 2006 123 133
4. S. Bhowmick, T. Mazumdar, R. Sinha, and N. Ali Comparison of liposome based antigen delivery systems for protection against Leishmania donovani J. Control. Release 141 2010 199 207
5. D. Peer, J.M. Karp, S. Hong, O.C. Farokhzad, R. Margalit, and R. Langer Nanocarriers as an emerging platform for cancer therapy Nat. Nanotechnol. 2 2007 751 760
6. T.M. Allen, and F.J. Martin Advantages of liposomal delivery systems for anthracyclines Semin. Oncol. 31 2004 5 15
7. R. Soloman, and A.A. Gabizon Clinical pharmacology of liposomal anthracyclines: focus on pegylated liposomal doxorubicin Clin. Lymphoma Myeloma 8 2008 21 32
8. D. Peer, and R. Margalit Loading mitomycin C inside long circulating hyaluronan targeted nano-liposomes increases its antitumor activity in three mice tumor models Int. J. Cancer 108 2004 780 789
9. D. Peer, and R. Margalit Tumor-targeted hyaluronan nano-liposomes increase the antitumor activity of liposomal doxorubicin in syngeneic and human xenograft mouse tumor models Neoplasia 6 2004 343 353
10. A. Gabizon, H. Shmeeda, and Y. Barenholz Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies Clin. Pharmacokinet. 42 5 2003 419 436
11. V.P. Torchilin Recent advances with liposomes as pharmaceutical carriers Nat. Rev. Drug Discov. 4 2005 145 150
12. C. Nathan Points of control in inflammation Nature 420 2002 846 852
13. T.J. Kindt, R.A. Goldsby, B.A. Osborne, and J. Kuby Kuby Immunology 2006 W.H. Freeman
14. T.A. Hamilton, Y. Ohmori, J.M. Tebo, and R. Kishore Regulation of macrophage gene expression by pro- and anti-inflammatory cytokines Pathobiology 67 1999 241 244
15. B.A. Beutler The role of tumor necrosis factor in health and disease J. Rheumatol. Suppl. 57 1999 16 21
16. D.F. Fiorentino, A. Zlotnik, T.R. Mosmann, M. Howard, and A. O'Garra IL-10 inhibits cytokine production by activated macrophages J. Immunol. 147 1991 3815 3822
17. R. Margalit, M. Okon, N. Yerushalmi, and E. Avidor Bioadhesive liposomes as topical drug delivery systems: molecular and cellular studies J. Control. Release 19 1992 275 287
18. N. Yerushalmi, A. Arad, and R. Margalit Molecular and cellular studies of hyaluronic acid-modified liposomes as bioadhesive carriers for topical drug delivery in wound healing Arch. Biochem. Biophys. 313 1994 267 273
19. D. Peer, and R. Margalit Physicochemical evaluation of a stability-driven approach to drug entrapment in regular and in surface-modified liposomes Arch. Biochem. Biophys. 383 2000 185 190
20. I. Elron-Gross, Y. Glucksam, D. Melikhov, and R. Margalit Cyclooxygenase inhibition by diclofenac formulated in bioadhesive carriers Biochim. Biophys. Acta 1778 2008 931 936
21. A. Aderem, and D.M. Underhill Mechanisms of phagocytosis in macrophages Annu. Rev. Immunol. 17 1999 593 623
22. N. Araki, M.T. Johnson, and J.A. Swanson A role for phosphoinositide 3-kinase in the completion of macropinocytosis and phagocytosis by macrophages J. Cell Biol. 135 1996 1249 1260
23. D. Peer, A. Florentin, and R. Margalit Hyaluronan is a key component in cryoprotection and formulation of targeted unilamellar liposomes Biochim. Biophys. Acta 1612 2003 76 82
24. Q. Li, and B.J. Cherayil Role of toll-like receptor 4 in macrophage activation and tolerance during salmonella enterica serovar typhimurium infection Infect. Immun. 71 2003 4873 4882
25. I. Rivkin, K. Cohen, J. Koffler, D. Melikhov, D. Peer, and R. Margalit Paclitaxel-clusters coated with hyaluronan as selective tumor-targeted nanovectors Biomaterials 31 2010 7106 7114
26. R. Yatuv, M. Robinson, I. Dayan-Tarshish, and M. Baru The use of PeGylated liposomes in the development of drug delivery applications for the treatment of hemophilia Int. J. Nanomedicine 5 2010 581 591
27. S.M. Ryan, G. Mantovani, X. Wang, D.M. Haddleton, and D.J. Brayden Advances in PEGylation of important biotech molecules: delivery aspects Expert Opin. Drug Deliv. 5 4 2008 371 383
28. M.L. Immordino, F. Dosio, and L. Cattel Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential Int. J. Nanomedicine 1 3 2006 297 315
29. J.W. Park Liposome-based drug delivery in breast cancer treatment Breast Cancer Res. 4 3 2002 95 99
30. S. Mizrahy, S. Rebe Raz, M. Hasgaard, H. Liu, N. Soffer-Tsur, K. Cohen, R. Dvash, D. Landsman-Milo, M.G.E.G. Bremer, S. Moein Moghimi, and D. Peer Hyaluronan-coated nanoparticles: the influence of the molecular weight on CD44-hyaluronan interactions and on the immune response J. Control. Release 156 2 2011 231 238